Summary and clinical outcomes of 24 immunized NSCLC patients
| Pt. ID | Stage | Sex | ECOG PS | Previous treatment | Progression before vaccination | Group | Tumor histology | Number of immunizations | Period of vaccination (weeks) | Treatment-related adverse events | Tumor response | PFS (months) | Treatments after vaccination |
| Pt. 1 | IV | F | 0 | SR, RT | RECIST-PD | 1 | Sq | 12 | 11.0 | No | PD | 4.9 | CM |
| Pt. 2 | IV | F | 2 | RT, CM | RECIST-PD | 1 | Ad | 24 | 23.0 | No | SD | 6.8 | No |
| Pt. 4 | IIIB | M | 3 | RT, CM | RECIST-PD, symptomatic PD | 1 | Sq | 12 | 10.4 | No | PD | 2 | No |
| Pt. 6 | IIIB | M | 1 | RT, CM | Symptomatic PD | 1 | Sq | 12 | 11.0 | No | SD | 3.9 | RT |
| Pt. 7 | IV | M | 2 | RT | Symptomatic PD | 1 | Sq | 12 | 11.0 | No | SD | 20.3 | No |
| Pt. 9 | IV | M | 1 | RT | RECIST-PD | 1 | Ad | 6 | 5.1 | No | SD | 3.4 | No |
| Pt. 10 | IIIA | M | 1 | RT | Symptomatic PD | 1 | Sq | 12 | 11.0 | No | PD | 2.7 | No |
| Pt. 19 | IV | F | 3 | RT,CM | RECIST-PD, symptomatic PD | 1 | Ad | 9 | 8.0 | Fever | PD | 1.7 | No |
| Pt. 11 | IV | F | 2 | RT,CM, EGFRi | RECIST-PD | 2 | Ad | 24 | 24.0 | No | PR | 8.6 | No |
| Pt. 14 | IIIB | M | 2 | SR,RT,CM, EGFRi | RECIST-PD, symptomatic PD | 2 | Sq | 12 | 11.0 | No | PR | 7.6 | No |
| Pt. 16 | IV | M | 2 | RT, CM, EGFRi | Symptomatic PD | 2 | Ad | 12 | 11.0 | No | SD | 4.2 | No |
| Pt. 17 | IV | F | 1 | SR, EGFRi | RECIST-PD | 2 | Ad | 49 | 51.0 | No | CR | 14.9 | No |
| Pt. 18 | IIIB | F | 1 | CM, EGFRi | RECIST-PD, symptomatic PD | 2 | Ad | 12 | 11.0 | Rash, Fatigue | PD | 1.9 | No |
| Pt. 20 | IV | M | 3 | CM, EGFRi | RECIST-PD, symptomatic PD | 2 | Ad | 7 | 5.9 | No | PD | 2.8 | No |
| Pt. 24 | IV | F | 0 | SR,CM, EGFRi | RECIST-PD | 2 | Ad | 12 | 11.0 | No | PD | 2.6 | EGFRi |
| Pt. 3 | IV | M | 1 | CM, EGFRi | Symptomatic PD | 3 | Ad | 27 | 37.9 | Fatigue | SD | 24.8 | No |
| Pt. 5 | IV | F | 1 | RT, CM, EGFRi | RECIST-PD | 3 | Ad | 48 | 79.6 | No | PR | 20 | No |
| Pt. 8 | IV | F | 2 | RT, EGFRi | RECIST-PD | 3 | Ad | 18 | 30.9 | No | PR | 9.5 | No |
| Pt. 12 | IV | F | 1 | RT,CM, EGFRi | RECIST-PD | 3 | Ad | 65 | 70.6 | No | PR | 18 | No |
| Pt. 13 | IV | F | 3 | CM, EGFRi | Symptomatic PD | 3 | Ad | 13 | 13.4 | No | SD | 8.9 | No |
| Pt. 15 | IV | F | 2 | RT,CM, EGFRi | Symptomatic PD | 3 | Ad | 12 | 11.0 | No | SD | 13.8 | No |
| Pt. 21 | IV | M | 1 | RT,CM, EGFRi | Symptomatic PD | 3 | Ad | 23 | 22.3 | No | SD | 5.2 | No |
| Pt. 22 | IV | F | 3 | RT, EGFRi | RECIST-PD | 3 | Ad | 33 | 33.0 | No | PR | 8.7 | No |
| Pt. 23 | IV | F | 0 | RT,CM, EGFRi | RECIST-PD | 3 | Ad | 24 | 24.0 | No | PD | 2.9 | No |
RECIST V.1.1 criteria were used to assess patient responses.
AD, adenocarcinoma; CM, chemotherapy; CR, complete response; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; EGFRi, EGFR inhibitor; F, female; M, male; NSCLC, non-small cell lung cancer ; PD, progressive disease; PFS, progression-free survival; PR, partial response; PS, performance status; Pt., patient; RT, radiotherapy; SD, stable disease; SQ, squamous cell carcinoma; SR, surgery.